Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure: Data From the European Sleep Apnea Database

Autor: Maria R. Bonsignore, Jean L. Pepin, Fabio Cibella, Calogero D. Barbera, Oreste Marrone, Johan Verbraecken, Tarja Saaresranta, Ozen K. Basoglu, Georgia Trakada, Izolde Bouloukaki, Walter T. McNicholas, Sébastien Bailly, Athanasia Pataka, John A. Kvamme, Holger Hein, Stefan Mihaicuta, Ludger Grote, Francesco Fanfulla, ESADA Study Group
Přispěvatelé: Università degli studi di Palermo - University of Palermo, Hypoxie et PhysioPathologie (HP2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Institute for Biomedical Research and Innovation Palermo, Antwerp University Hospital [Edegem] (UZA), University of Turku, Izmir University of Economics (IUE), National and Kapodistrian University of Athens (NKUA), University of Crete [Heraklion] (UOC), St Vincent's Hospital Group Dublin Ireland, Aristotle University of Thessaloniki, Foerde Central Hospital, Private Practice and Sleep Lab for Internal Medicine, Pulmonary Medicine and Sleep Medicine, Geesthacht, Germany, Victor Babes University of Medicine and Pharmacy, CardioPrevent Foundation, Timisoara, Romania., Sahlgrenska University Hospital, Gothenburg, Sweden., Fondazione IRCCS Policlinico San Matteo [Pavia], Università di Pavia, ANR-19-P3IA-0003,MIAI,MIAI @ Grenoble Alpes(2019), ESADA Study Group, Bonsignore M.R., Pepin J.L., Cibella F., Barbera C.D., Marrone O., Verbraecken J., Saaresranta T., Basoglu O.K., Trakada G., Bouloukaki I., McNicholas W.T., Bailly S., Pataka A., Kvamme J.A., Hein H., Mihaicuta S., Grote L., Fanfulla F.
Jazyk: angličtina
Rok vydání: 2021
Předmět:
sleep latency
Residual Sleepiness
medicine.medical_treatment
[SDV]Life Sciences [q-bio]
Excessive daytime sleepiness
Settore MED/10 - Malattie Dell'Apparato Respiratorio
computer.software_genre
Cpap adherence
03 medical and health sciences
0302 clinical medicine
Interquartile range
Cpap Use
medicine
follow-up
Continuous positive airway pressure
Obesity
RC346-429
ComputingMilieux_MISCELLANEOUS
residual sleepness
Original Research
Wake-Active Neurons
Database
business.industry
residual sleepine
Epworth Sleepiness Scale
Sleep apnea
Epworth sleepness Scale
medicine.disease
CPAP adherence
Important Difference
nervous system diseases
respiratory tract diseases
Scale
Obstructive sleep apnea
Lifestyle factors
030228 respiratory system
Neurology
sleep duration
Human medicine
Neurology. Diseases of the nervous system
Neurology (clinical)
medicine.symptom
business
computer
030217 neurology & neurosurgery
Zdroj: Frontiers in Neurology
Frontiers in Neurology, Frontiers, 2021
Frontiers in Neurology, Vol 12 (2021)
Frontiers in neurology 12 (2021). doi:10.3389/fneur.2021.690008
info:cnr-pdr/source/autori:Bonsignore MR; Pepin JL; Cibella F; Barbera CDG; Marrone O; Verbraecken J; Saaresranta T; Basoglu OK; Trakada G; Bouloukaki I; McNicholas WT; Bailly S; Pataka A1; Kvamme JA; Hein H; Mihaicuta S; Grote L; Fanfulla F/titolo:Excessive daytime sleepiness in obstructive sleep apnea (OSA) patients treated with continuous positive airway pressure (CPAP): data from the European Sleep Apnea Database (ESADA)/doi:10.3389%2Ffneur.2021.690008/rivista:Frontiers in neurology/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:12
Frontiers in neurology
ISSN: 1664-2295
DOI: 10.3389/fneur.2021.690008
Popis: Excessive daytime sleepiness (EDS) is a symptom of obstructive sleep apnea (OSA) that resolves under treatment with continuous positive airway pressure (CPAP). In some patients, sleepiness persists despite CPAP treatment. We retrospectively analyzed data on subjective residual EDS, assessed as an Epworth Sleepiness Scale score (ESS) >10, in patients from the European Sleep Apnea Database (n = 4,853, mean age +/- SD 54.8 +/- 11.8 years, 26.1% females), at baseline and at the first visit (median follow-up: 5 months, interquartile range 3-13). An ESS > 10 occurred in 56% of patients at baseline and in 28.2% of patients at follow-up. Residual EDS was analyzed in 2,190 patients (age: 55.1 +/- 12.0 years, 26.1% females) with sleep monitoring data (median follow-up: 3 months, interquartile range 1-15). Sleep studies during CPAP use were obtained in 58% of these patients; EDS was reported by 47.2% of patients at baseline and by 30.3% at follow-up. Residual OSA, defined as an apnea-hypopnea index >10/h, and insufficient CPAP adherence, defined as nightly use 10 at the first follow-up visit was associated directly with ESS at baseline and inversely with duration of follow-up, and CPAP use (R-2 of themodel: 0.417). EDS showed heterogeneity in different European countries both at baseline and at the first follow-up visit, suggesting modulation by cultural and lifestyle factors. In conclusion, residual EDS in CPAP-treated OSA occurred in approximately one in four patients at follow-up; its prevalence was highest (40%) in the first 3 months of treatment and subsequently decreased. The finding of residual EDS in a significant percentage of optimally treated OSA patients suggests that wake-promoting agents may be useful, but their indication should be evaluated after at least 3 months of treatment.
European Respiratory Society; ResMed; Philips; Bayer Pharmaceuticals; MIAI @ Grenoble Alpes [ANR19P3IA0003]
The ESADA study is a Clinical Research Collaboration funded by the European Respiratory Society and by grants from ResMed, Philips and Bayer Pharmaceuticals. JP and SB are partly supported by MIAI @ Grenoble Alpes (ANR19P3IA0003) . The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Databáze: OpenAIRE
Externí odkaz: